GTHX - G1セラピュ―ティクス (G1 Therapeutics Inc.) G1セラピュ―ティクス

 GTHXのチャート


 GTHXの企業情報

symbol GTHx
会社名 G1 Therapeutics Inc (G1セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 G1セラピューティクス(G1 Therapeutics Inc.)は臨床段階のバイオ医薬品会社である。同社はがん治療用小分子療法の開発に従事する。同社の2つの臨床段階の候補はキナーゼ標的CDK4 / 6の選択的阻害剤であるトリラシクリブ(G1T28)およびG1T38である。トリラシクリブおよびG1T38は現在の治療法の抗腫瘍活性を増強するように設計される。同社はまた、乳癌の治療用経口選択的エストロゲン受容体分解酵素(SERD)であるG1T48を開発中である。3つの第II相臨床試験において、同社はトリラシクリブを評価する。G1T38はエストロゲン受容体陽性HER2陰性乳癌患者のフェーズI b / II試験において、Faslodexと組み合わせて評価される。   G1セラピュ―ティクスは米国のバイオ医薬品企業。臨床ステ―ジで、がん治療の新薬や治療法の発見・開発に従事する。細胞肺がんの治療用サイクリン依存性キナ―ゼ(CDK)4/6阻害薬と、乳がん治療用の経口タイプCDK4/6阻害薬やエストロゲン受容体ディグレ―ダ―などの新薬を開発する。本社所在地はノ―スカロライナ州リサ―チ・トライアングル・パ―ク。   G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
本社所在地 79 T.W. Alexander Drive 4501 Research Commons Suite 100 Research Triangle Park NC 27709 USA
代表者氏名 Seth A. Rudnick Seth A. Rudnick
代表者役職名 Independent Chairman of the Board
電話番号 +1 919-213-9835
設立年月日 39569
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数
url www.g1therapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/gthx
adr_tso
EBITDA EBITDA(百万ドル) -75.46400
終値(lastsale) 43.93
時価総額(marketcap) 1467461222.55
時価総額 時価総額(百万ドル) 1688.8
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 1500.573
当期純利益 当期純利益(百万ドル) -73.86000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 G1 Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 28% to $41.3M. Higher net loss reflects Research_Development - Balancing value increase of 40% to $33.3M (expense) General and Administrative - Balancing increase of 100% to $5.4M (expense) Stock-based Compensation in R&D increase from $1M to $2.4M (expense).

 GTHXのテクニカル分析


 GTHXのニュース

   The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results  2020/07/23 12:25:53 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioLife Solutions Inc (NASDAQ: BLFS ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunic Inc (NASDAQ: IMUX ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) ( reported forecast-beating second-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Novo Nordisk A/S (NYSE: NVO ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Otonomy Inc (NASDAQ: OTIC ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) Akouos Inc (NASDAQ: AKUS ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Nkarta Inc (NASDAQ: NKTX ) RENALYTIX AI ADR (NASDAQ: RNLX ) (went public Friday) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Midatech Terminates Sale Process, Strategic Review to Continue Midatech Pharma PLC-ADR (NASDAQ: MTP ), a drug delivery technology company, said it has terminated the formal sale process initiated in late April after it failed to receive any proposals from third parties.
   The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results  2020/07/23 08:25:00 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: …
   Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More  2019/09/30 13:13:00 Benzinga
The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where …
   Harry Boxer’s three biotech stocks on the move include Nektar Therapeutics  2019/06/19 17:58:00 MarketWatch
Also in focus: G1 Therapeutics and Iovance Biotherapeutics.
   G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer  2019/06/18 10:00:00 Yahoo Finance
G1 Therapeutics, Inc. (GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy
   The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results  2020/07/23 12:25:53 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioLife Solutions Inc (NASDAQ: BLFS ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunic Inc (NASDAQ: IMUX ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) ( reported forecast-beating second-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Novo Nordisk A/S (NYSE: NVO ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Otonomy Inc (NASDAQ: OTIC ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) Akouos Inc (NASDAQ: AKUS ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Nkarta Inc (NASDAQ: NKTX ) RENALYTIX AI ADR (NASDAQ: RNLX ) (went public Friday) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Midatech Terminates Sale Process, Strategic Review to Continue Midatech Pharma PLC-ADR (NASDAQ: MTP ), a drug delivery technology company, said it has terminated the formal sale process initiated in late April after it failed to receive any proposals from third parties.
   The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results  2020/07/23 08:25:00 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: …
   Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More  2019/09/30 13:13:00 Benzinga
The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where …
   Harry Boxer’s three biotech stocks on the move include Nektar Therapeutics  2019/06/19 17:58:00 MarketWatch
Also in focus: G1 Therapeutics and Iovance Biotherapeutics.
   G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer  2019/06/18 10:00:00 Yahoo Finance
G1 Therapeutics, Inc. (GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy
   The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results  2020/07/23 12:25:53 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioLife Solutions Inc (NASDAQ: BLFS ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunic Inc (NASDAQ: IMUX ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) ( reported forecast-beating second-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Novo Nordisk A/S (NYSE: NVO ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Otonomy Inc (NASDAQ: OTIC ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) Akouos Inc (NASDAQ: AKUS ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Nkarta Inc (NASDAQ: NKTX ) RENALYTIX AI ADR (NASDAQ: RNLX ) (went public Friday) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Midatech Terminates Sale Process, Strategic Review to Continue Midatech Pharma PLC-ADR (NASDAQ: MTP ), a drug delivery technology company, said it has terminated the formal sale process initiated in late April after it failed to receive any proposals from third parties.
   The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results  2020/07/23 08:25:00 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: …
   Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More  2019/09/30 13:13:00 Benzinga
The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where …
   Harry Boxer’s three biotech stocks on the move include Nektar Therapeutics  2019/06/19 17:58:00 MarketWatch
Also in focus: G1 Therapeutics and Iovance Biotherapeutics.
   G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer  2019/06/18 10:00:00 Yahoo Finance
G1 Therapeutics, Inc. (GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 G1セラピュ―ティクス GTHX G1 Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)